IP Library Granted Patent US 10,231,997
Granted Patent B2
US 10,231,997 · App. 14/420,680 · Granted Mar 19, 2019

Exosome-based therapeutics against neurodegenerative disorders

Inventors: Kae M. Pusic (Chicago, IL); Yelena Y. Grinberg (Chicago, IL); Richard P. Kraig (Chicago, IL); Aya D. Pusic (Chicago, IL)
Assignee: The University of Chicago
A61K35/15A61K9/5068A61K31/7088A61K35/30A61K35/35A61K48/00C12N5/0618C12N15/111C12N15/113C12N15/88C12N2310/14C12N2310/141C12N2320/31C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,231,997
App. No.
14/420,680
Granted
Mar 19, 2019
Kind
B2
Abstract

Methods and compositions involving exosomes or lipid nanovesicles are provided. For example, certain aspects relate to compositions comprising exosomes obtained from cells that have been induced to undergo oxidative stress or stimulated. Furthermore, some aspects of the invention provide methods of treating a subject at risk or having a demyelinating disorder using the compositions.

Claims (9)

1. A method for treating a patient having a demyelinating disorder comprising administering to the patient an effective amount of a pharmaceutical composition comprising isolated exosomes obtained from cells that have been incubated with IFN-γ, wherein the cells are dendritic cells.

2. The method of claim 1 , wherein the demyelinating disorder is cognitive decline, Alzheimer's disease, Parkinson's disease, stroke, epilepsy, migraine, multiple sclerosis, or neuropathy.

3. The method of claim 1 , wherein the isolated exosomes have at least two different types of exosomes.

4. The method of claim 1 , wherein the cells are cells obtained from the patient.

5. The method of claim 1 , wherein the isolated exosomes comprise an externally added therapeutic agent comprising an siRNA.

6. The method of claim 1 , wherein the isolated exosomes comprise miR-219, miR-138, or miR-199a.

7. The method of claim 1 , wherein the isolated exosomes comprise mRNA encoding antioxidant system proteins.

8. The method of claim 1 , wherein the administering step causes growth or repair of myelin in the patient.

9. The method of claim 1 , wherein the isolated exosomes are enriched for miRNAs that promote oligodendrocyte differentiation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2015
From: KRAIG, RICHARD P.; PUSIC, AYA D.; GRINBERG, YELENA Y.; PUSIC, KAE M.
To: THE UNIVERSITY OF CHICAGO
Reel/Frame 035349/0001 →
Continuity (2)
Provisional Application 61683596 · Aug 15, 2012
Related Publication 20150216899A1 · Aug 6, 2015